A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Nanthapisal, Sira; Puthanakit, Thanyawee; Jaru-Ampornpan, Peera; Nantanee, Rapisa; Sodsai, Pimpayao; Himananto, Orawan; Sophonphan, Jiratchaya; Suchartlikitwong, Pintip; Hiransuthikul, Narin; Angkasekwinai, Pornpimon; Tangsathapornpong, Auchara; Hirankarn, Nattiya

doi:10.1016/j.vaccine.2022.03.036

Cited by 11 publications

(12 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The ELISA protocol was adapted from Amanat et al [ 25 ] and performed as described previously [ 26 ]. The ELISA plates were coated with purified recombinant Myc-His-tagged S-RBD, residues 319–541 from SARS-CoV-2 (Wuhan-Hu-1).…”

Section: Methodsmentioning

confidence: 99%

“…A surrogate virus neutralization test was set up as previously described in Tan et al [ 27 ] and our previous work [ 26 ]. Recombinant S-RBD (residues 319–541) from Delta (B.1.617.2) or Omicron (B.1.1.529; BA.1) strains and the ectodomain of human ACE2 were purified from Human Embryonic Kidney (HEK) 293T cells.…”

Section: Methodsmentioning

confidence: 99%

“…In the post-booster group, the questionnaires were performed before getting the booster vaccination and then an appointment for blood collection subsequently followed. The ELISA protocol was adapted from Amanat et al [25] and performed as described previously [26]. The ELISA plates were coated with purified recombinant Myc-His-tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1).…”

Section: Study Proceduresmentioning

confidence: 99%

See 2 more Smart Citations

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

et al. 2022

Self Cite

View full text Add to dashboard Cite

Despite the BNT162b2 vaccination coverage, rapid transmission of Omicron SARS-CoV-2 has occurred, which is suspected to be due to the immune escape of the variant or waning vaccine efficacy of multiple BNT162b2 vaccination doses. Our study aims to compare immunogenicity against Omicron prior to and post a booster dose of BNT162b2 in healthy adolescents, and to evaluate their attitudes toward booster dose vaccination. A cross sectional study was conducted among healthy adolescents aged 12–17 who received two doses of BNT162b2 more than 5 months ago. Participants and their guardians performed self-reported questionnaires regarding reasons for receiving the booster. A 30 ug booster dose of BNT162b2 was offered. Immunogenicity was evaluated by a surrogate virus neutralization test (sVNT) against the Omicron variant, and anti-spike-receptor-binding-domain IgG (anti-S-RBD IgG) taken pre-booster and 14-days post-booster. From March to April 2022, 120 healthy Thai adolescents with a median age of 15 years (IQR 14–16) were enrolled. sVNT against Omicron pre- and post-booster had 11.9 (95%CI 0–23.9) and 94.3 (90.6–97.4) % inhibition. Geometric means (GMs) of anti-S-RBD IgG increased from 837 (728, 953) to 3041 (2893, 3229) BAU/mL. Major reasons to receive the booster vaccination were perceived as vaccine efficacy, reduced risk of spreading infection to family, and safe resumption of social activities. A booster dose of BNT162b2 elicits high immunogenicity against the Omicron variant. Motivation for receiving booster doses is to reduce risk of infection.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Study Proceduresmentioning

confidence: 99%

See 1 more Smart Citation

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

et al. 2022

Self Cite

View full text Add to dashboard Cite

show abstract

“…The ELISA protocol was modified from Amanat et al [20] and performed as described previously [21] , [22] . Briefly, the ELISA plates were coated with purified recombinant Myc-His-tagged S-RBD, residues 319-541 from SARS-CoV-2 (Wuhan-Hu-1).…”

Section: Methodsmentioning

confidence: 99%

“…The surrogate virus neutralization test was adjusted from Tan et al (2020) [23] and performed as described previously [21] , [22] , utilizing the HRP-tagged recombinant SRBD from the wild-type (Wuhan-Hu-1), Delta (B.1.617.2), and Omicron (B.1.1.529 – BA.1) strains. The 96-well plates coated with 0.1 µg/well purified recombinant human ACE2 ectodomain were used to incubate with serum samples (at 1:10 dilution) - SRBD mixture.…”

Section: Methodsmentioning

confidence: 99%

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

et al. 2022

Self Cite

View full text Add to dashboard Cite

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

et al. 2023

View full text Add to dashboard Cite

A randomized clinical trial of a booster dose with low versus standard dose of AZD1222 in adult after 2 doses of inactivated vaccines

Cited by 11 publications

References 25 publications

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

Immunogenicity of BNT162b2 Vaccination against SARS-CoV-2 Omicron Variant and Attitudes toward a COVID-19 Booster Dose among Healthy Thai Adolescents

Heterologous Prime-boost of SARS-CoV-2 inactivated vaccine and mRNA BNT162b2 among Healthy Thai Adolescents

Humoral response after a BNT162b2 heterologous third dose of COVID-19 vaccine following two doses of BBIBP-CorV among healthcare personnel in Peru

Contact Info

Product

Resources

About